ClinicalTrials.gg
CompletedNCT02232061Updated Feb 10, 2021Results posted

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

A Phase 4 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
32nd of 34
6 · median 167
Started
2014
with 1 other
Phase 4
17 of 34
none open now
Registered
27th of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 32nd largest by enrollment, is one of 2 that started in 2014, is one of 17 in phase 4, and was the 27th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events

Read the detailed description

This was a multi-national, long-term safety study. Patients enrolled in study FTY720D2406 who experienced a cardiovascular event within 24-hours of fingolimod treatment initiation which led to overnight monitoring or met serious adverse event criteria, were eligible to participate in this study.

Patients who experienced a qualifying event in study CFTY720D2406 started study CFTY720D2409 approximately 6 months after the occurrence of the CFTY720D2406 qualifying event.

Patients underwent mandatory assessments on a 6-monthly basis including 12-lead ECG, vital signs. Other assessments were performed as per routine practice.

The primary objective of the study was to estimate the long-term cardiovascular risk of fingolimod in patients who experienced a cardiovascular event during treatment initiation.

The study has no stand-alone secondary objective. However data from the CFTY720D2409 and CFTY720D2406 studies will be pooled to supplement CFTY720DD2406 study and support its primary and secondary objectives of evaluating the safety profile of fingolimod.

The pooled data will be appended to this result upon completion of FDA submission.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • multiple sclerosis, fingolimod, adult, FTY720, inflammatory disease, demyelination, auto-inflammatory disease, relapsing-remitting MS, CFTY720D2406
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients participating in study FTY720D2406 who experienced a serious cardiovascular event during their fingolimod treatment initiation or re-initiation which led to overnight monitoring or met seriousness criteria.
  • Patients still on fingolimod after the this first dose serious event

Exclusion criteria

Exclusion Criteria:

-Treatment with any drug unless it is received as part of a Novartis sponsored MS study lasting less than 1 month

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Fingolimod 0.5mg/day tablets taken orally.

    Drug: Fingolimod

Interventions

  • Fingolimod 0.5 mg tablet

    Also known as: FTY720

06

What researchers measure

Primary outcomes

  1. Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event

    Participants from study CFTY720D2406 who experienced a qualifying cardiovascular adverse event were transferred to this study. Qualifying cardiovascular events included, but were not limited to, sudden unexplained death, cardiovascular death, myocardial infarction (MI), Q-wave MI, stroke (ischemic or hemorrhagic), unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, complete heart block, ventricular fibrillation, torsade de pointes, hypertensive emergency and any other suspected life threatening cardiovascular condition.

    Time frame: Within 6 months of qualifying event up to 64 months

07

Results

Posted Feb 10, 2021
Limitations and caveats
This study had no stand-alone secondary objectives. However, data from the CFTY720D2409 and D2406 studies will be pooled to supplement this study and will be appended to this record when available.

Participant flow

Participant flow — Overall Study
MilestoneFingolimod
Started6
Completed4
Not completed2
Withdrew: Administrative problems1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryParticipants Who Experienced at Least One Qualifying Cardiovascular Adverse Event

Participants from study CFTY720D2406 who experienced a qualifying cardiovascular adverse event were transferred to this study. Qualifying cardiovascular events included, but were not limited to, sudden unexplained death, cardiovascular death, myocardial infarction (MI), Q-wave MI, stroke (ischemic or hemorrhagic), unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, complete heart block, ventricular fibrillation, torsade de pointes, hypertensive emergency and any other suspected life threatening cardiovascular condition.

Time frame:
Within 6 months of qualifying event up to 64 months
Reported as:
Number · participants
Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event
participantsFingolimod
Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event0

Adverse events

Collected over Within 6 months of qualifying event up to approximately 64 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod0/6 (0%)2/6 (33.3%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventFingolimod
LYMPHOPENIABlood and lymphatic system disorders1/6
BRONCHITIS VIRALInfections and infestations1/6
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6
ASTHMARespiratory, thoracic and mediastinal disorders1/6
Most frequent other events
Showing 10 of 24
Most frequent other events
EventFingolimod
LYMPHOPENIABlood and lymphatic system disorders1/6
HYPOTHYROIDISMEndocrine disorders1/6
HAEMORRHOIDAL HAEMORRHAGEGastrointestinal disorders1/6
PYREXIAGeneral disorders1/6
NASOPHARYNGITISInfections and infestations1/6
TRICHOMONIASISInfections and infestations1/6
VIRAL PHARYNGITISInfections and infestations1/6
INFUSION RELATED REACTIONInjury, poisoning and procedural complications1/6
FOLATE DEFICIENCYMetabolism and nutrition disorders1/6
HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders1/6

Baseline characteristics

Age, Customized
Age, Customized(participants)Fingolimod
Ages 21 - 476
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod
Female5
Male1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fingolimod
Caucasian6
08

Study locations

4 sites
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Hasselt, 3500, Belgium
  • Novartis Investigative Site
    Ravensburg, 88212, Germany
  • Novartis Investigative Site
    Napoli, 80131, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2020, 63 months.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 63 months is above that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2014
First posted
Sep 4, 2014
StartActual
Sep 29, 2014
Primary completionActual
Jan 24, 2020
CompletionActual
Jan 24, 2020
Results first posted
Feb 10, 2021
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02232061
Responsible party
Sponsor
First posted
Sep 4, 2014
Start date
Sep 29, 2014
Primary completion
Jan 24, 2020
Completion
Jan 24, 2020
Results posted
Feb 10, 2021
Last update
Feb 10, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion